Venus Concept (NASDAQ:VERO – Get Rating) and Stevanato Group (NYSE:STVN – Get Rating) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, risk, analyst recommendations, earnings and institutional ownership.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Venus Concept and Stevanato Group, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Venus Concept | 0 | 1 | 2 | 0 | 2.67 |
| Stevanato Group | 0 | 0 | 4 | 0 | 3.00 |
Stevanato Group has a consensus target price of €30.50 ($32.80), indicating a potential downside of 5.78%. Given Venus Concept’s higher probable upside, analysts plainly believe Venus Concept is more favorable than Stevanato Group.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Venus Concept | $99.50 million | 0.13 | -$43.70 million | ($9.65) | -0.24 |
| Stevanato Group | $1.04 billion | 9.23 | $150.51 million | €0.57 ($0.61) | 56.79 |
Stevanato Group has higher revenue and earnings than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Venus Concept and Stevanato Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Venus Concept | -47.79% | -426.69% | -36.40% |
| Stevanato Group | 14.17% | 15.15% | 9.00% |
Volatility & Risk
Venus Concept has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.
Institutional & Insider Ownership
10.3% of Stevanato Group shares are owned by institutional investors. 51.4% of Venus Concept shares are owned by insiders. Comparatively, 0.7% of Stevanato Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Stevanato Group beats Venus Concept on 11 of the 14 factors compared between the two stocks.
About Venus Concept
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes aesthetic device platforms, including Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada.
About Stevanato Group
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for pharma and healthcare. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. operates as a subsidiary of Stevanato Holding S.R.L.
Receive News & Ratings for Venus Concept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Venus Concept and related companies with MarketBeat.com's FREE daily email newsletter.
